Tamarack Advisers’s Jazz Pharmaceuticals JAZZ Stock Holding History

Tamarack Advisers’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-30,000	Closed	-$4M	–	43
2022 Q3	$4M	Buy	30,000 +5,000	+20%	+$760K	2.35%	19
2022 Q2	$3.9M	Sell	25,000 -5,000	-17%	-$770K	2.26%	19
2022 Q1	$4.67M	Buy	30,000 +5,000	+20%	+$726K	2.21%	17
2021 Q4	$3.19M	Buy	+25,000	New	+$3.29M	1.31%	28
2017 Q3	–	Sell	-55,000	Closed	-$8.55M	–	39
2017 Q2	$8.55M	Sell	55,000 -2,000	-4%	-$306K	4.99%	8
2017 Q1	$8.27M	Sell	57,000 -20,000	-26%	-$2.6M	5.17%	6
2016 Q4	$8.39M	Sell	77,000 -23,000	-23%	-$2.56M	5.94%	6
2016 Q3	$12.1M	Buy	+100,000	New	+$13.5M	3.8%	12

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Tamarack Advisers's JAZZ Position: Q4 2022 in Review

Tamarack Advisers sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2022, closing a stake of 30,000 shares — an estimated $4M sold.

Tamarack Advisers first reported a position in JAZZ in Q3 2016 and held it in 8 quarters. The position peaked at $12.1M in Q3 2016. 485 funds tracked by Wall St. Rank hold JAZZ as of Q4 2022.

Tamarack Advisers reported no remaining Jazz Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Tamarack Advisers sold 30,000 Jazz Pharmaceuticals shares in Q4 2022, an estimated $4M.
Tamarack Advisers first reported a position in Jazz Pharmaceuticals in Q3 2016 and held it in 8 quarters.
Tamarack Advisers's Jazz Pharmaceuticals position peaked at $12.1M in Q3 2016.
485 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2022.

Based on Tamarack Advisers's 13F filing for Q4 2022, filed 13 Feb 2023.